Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Investment analysts at Piper Jaffray Companies dropped their FY2021 earnings per share (EPS) estimates for shares of Biohaven Pharmaceutical in a report released on Wednesday, September 12th. Piper Jaffray Companies analyst T. Van. Buren now anticipates that the company will post earnings per share of ($2.25) for the year, down from their previous estimate of ($1.90). Piper Jaffray Companies has a “Buy” rating and a $65.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Biohaven Pharmaceutical’s FY2022 earnings at $0.70 EPS.
Several other brokerages have also recently weighed in on BHVN. Barclays raised their price target on shares of Biohaven Pharmaceutical to $40.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 19th. Morgan Stanley raised their price target on shares of Biohaven Pharmaceutical from $39.00 to $44.00 and gave the stock an “overweight” rating in a research note on Friday, July 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven Pharmaceutical in a research note on Thursday, June 14th. Canaccord Genuity set a $40.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Sunday, July 1st. Finally, Needham & Company LLC raised their price target on shares of Biohaven Pharmaceutical from $36.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, July 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $47.29.
Shares of BHVN opened at $35.86 on Monday. The company has a market cap of $1.55 billion, a PE ratio of -7.17 and a beta of 1.42. Biohaven Pharmaceutical has a twelve month low of $16.50 and a twelve month high of $44.28.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BHVN. Wells Fargo & Company MN boosted its holdings in shares of Biohaven Pharmaceutical by 38.2% in the 1st quarter. Wells Fargo & Company MN now owns 41,184 shares of the company’s stock valued at $1,060,000 after buying an additional 11,373 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Biohaven Pharmaceutical by 218.4% in the 1st quarter. Rhumbline Advisers now owns 27,933 shares of the company’s stock valued at $720,000 after buying an additional 19,160 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new stake in shares of Biohaven Pharmaceutical in the 1st quarter valued at approximately $329,000. Swiss National Bank boosted its holdings in shares of Biohaven Pharmaceutical by 104.6% in the 1st quarter. Swiss National Bank now owns 31,300 shares of the company’s stock valued at $806,000 after buying an additional 16,000 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Biohaven Pharmaceutical in the 1st quarter valued at approximately $832,000. 80.85% of the stock is owned by institutional investors.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Featured Article: How to Invest in Growth Stocks
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.